Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Beard SM, Lorigan P and Sampson FC (1999) The cost effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. Br J Cancer 0: 000–000
Bennett CL, Armitage JL and Armitage GO et al (1995) Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991. J Clin Oncol 13: 969–973
Desch CE, Lasala MR and Smith TJ, et al. (1992) The optimal timing of autologous bone marrow transplantation in Hodgkin's disease following a chemotherapy relapse. J Clin Oncol 10: 200–209
Haioun C, Lepage E and Gisselbrecht C, et al (1994) Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate- and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. J Clin Oncol 12: 2543–2551
Haioun C, Lepage E and Gisselbrecht C, et al (1997) Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87–2. J Clin Oncol 15: 1131–1137
Hartmann O, Le Corroller A and Blaise D, et al. (1997) Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. Ann Intern Med 126: 600–607
Johnson PWM, Simnett SJ and Sweetenham JW, et al (1998) Bone marrow and peripheral blood stem cell transplantation for malignancy. Health Technology Assessment 2: 8
Linch DC, Winfield D and Goldstone AH, et al. (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 341: 1051–1054
McQuaker IG, Hunter AE and Pacey S et al. (1997) Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 15: 451–457
Martelli M, Vignetti M and Zinzani PL, et al. (1996) High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. J Clin Oncol 14: 534–542
NCI Monograph (1998) Integrating economic analysis into clinical trials. the National Cancer Institute–American Society of Clinical Oncology Economics Workbook. Number 24
Philip T, Guglielmi C and Hagenbeek A et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333: 1540–1545
Schmitz N and Sextro M. Pfistner B et al (1999) High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease (HD): final results of a randomized GHSG and EBMT trial (HD-R1). Proc Am Soc Clin Oncol 18: 2a
Schulman KA, Birch R and Zhen B, et al (1999) Effect of CD34+cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol 17: 1227–1233
Smith TJ, Hillner BE and Schmitz N, et al (1997) Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 15: 5–10
Uyl-de Groot CA, Okhuijsen SY and Hagenbeek A, et al (1995 a) Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in the Netherlands. Bone Marrow Transpl 15: 605–610
Uyl-de Groot CA, Hagenbeek A and Verdonck LF (1995 b) Cost effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate and high grade malignant non-Hodgkin's lymphoma. Bone Marrow Transpl 16: 463–470
Westermann AM, Holtkamp MMJ and Linthorst GAM, et al. (1999) At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies. Ann Oncol 10: 511–517
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Sweetenham, J. Economics of stem cell transplantation for lymphoma: counting the cost of living. Br J Cancer 82, 4–6 (2000). https://doi.org/10.1054/bjoc.1999.0867
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.1999.0867
